- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07308860
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended: Uma Comparação da Intervenção Coronária Percutânea Guiada por Fractional Flow Reserve e da Cirurgia de Revascularização Miocárdica em Doentes com Doença Coronária Multivasos
Coronary artery disease, or narrowing of the blood vessels that provide blood to the heart, is the most common cause of death in the United States and can be treated with either coronary bypass surgery or coronary stent placement. This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Coronary artery disease (CAD) remains the major cause of morbidity and mortality in adults in the United States. In patients with 3-vessel CAD not involving the left main coronary artery, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) can improve outcomes. Older studies have shown that the more invasive option, CABG, significantly reduces mortality during long-term follow-up compared with PCI. However, these studies did not use contemporary methods to perform PCI, such as measuring an index called fractional flow reserve (FFR) with a coronary pressure wire or using current- generation drug-eluting stents (DES), both of which significantly improve outcomes after PCI. The Fractional flow reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial randomized 1,500 patients to FFR-guided PCI with current generation DES or to CABG and found that at 5 years there was no significant difference in the composite of death, myocardial infarction (MI) or stroke between the two strategies. There was a reduction in MI in the CABG group. Longer-term follow-up is critical to determine if contemporary PCI results in similar survival as CABG. The primary aim of this project is to determine if 10-year mortality is different after FFR-guided PCI compared with CABG. Investigators will perform 10-year follow-up in the 1,500 patients randomized in the FAME 3 trial to determine if FFR-guided PCI is non-inferior to CABG with respect to mortality. Secondary aims include assessing quality of life and angina relief at 10 years in the two groups. Additionally, investigators will compare individual rates of secondary clinical outcomes including MI, stroke, and repeat revascularization at 10-year follow-up after PCI or CABG.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.
Descrição
Inclusion Criteria:
-
Age ≥ 21 years with angina and/or evidence of myocardial ischemia
-
Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if only the left anterior descending artery (LAD) and left circumflex have
≥50% stenosis
-
Willing and able to provide informed, written consent
Exclusion Criteria:
- Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, carotid revascularization), however a maze procedure or pulmonary vein isolation is allowed
- Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
- Recent STEMI (<5 days prior to randomization)
- Ongoing Non STEMI with biomarkers (cardiac troponin) still rising
- Known left ventricular ejection fraction <30%
- Life expectancy < 2 years
- Requiring renal replacement therapy
- Undergoing evaluation for organ transplantation
- Participation or planned participation in another clinical trial, except for observational registries
- Pregnancy
- Inability to take dual antiplatelet therapy or anticoagulation and single antiplatelet therapy for at least six months
- Previous CABG
- Left main disease requiring revascularization
- Extremely calcified or tortuous vessels precluding FFR measurement
- Any target lesion with in-stent drug-eluting stent restenosis
- More than one major epicardial vessel which is chronically occluded
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
FFR-guided PCI group
These patients have undergone fractional flow reserve-guided percutaneous coronary intervention |
Coronary stenting compared with coronary bypass surgery |
|
CABG group
These patients underwent coronary artery bypass grafting surgery |
Coronary artery bypass surgery |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Survival
Prazo: 10-year follow-up
|
The primary outcome is mortality or overall survival |
10-year follow-up
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Quality of life
Prazo: 10-year follow-up
|
Secondary aims include assessing quality of life at 10 years in the two groups utilizing the EQ-5D quality of life questionnaire. |
10-year follow-up
|
|
Angina Relief
Prazo: 10 year follow-up
|
Secondary aims include assessing angina status at 10 years in the two groups utilizing the Seattle Angina Questionnaire. |
10 year follow-up
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Major adverse cardiac events
Prazo: 10 year follow-up
|
Additionally, we will compare individual rates of secondary clinical outcomes including myocardial infarction (MI), stroke, and repeat revascularization and combinations of the above, including death and MI, and death, MI, or stroke at 10-year follow-up after PCI or CABG. |
10 year follow-up
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Distúrbios Cerebrovasculares
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças cardíacas
- Infarte
- Necrose
- Arteriosclerose
- Doenças Arteriais Oclusivas
- Doença cardíaca
- Isquemia do miocárdio
- Isquemia
- Dor no peito
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Derrame
- Doença arterial coronária
- Morte
- Infarto do miocárdio
- Angina Pectoris
Outros números de identificação do estudo
- 83374
- 1R01HL179196-01 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .